SUBSCRIBE
SUBSCRIBE

Zoledronic Acid Works Faster than Alendronate, Philipps University Study

September 21, 2009 | 
1 min read

MedPage Today -- DENVER -- Biochemical markers of bone turnover showed significantly faster responses on initiation of once-yearly zoledronic acid (Reclast) infusion than with weekly oral alendronate (Fosamax), researchers said here.

Europe
MORE ON THIS TOPIC
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
A handshake of businessmen. Modern design with a positive context. Concept of help, support, and agreement between businessmen. Modern art collage, trendy magazine style.
Mergers & acquisitions
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
December 9, 2024
 · 
2 min read
 · 
Tristan Manalac
Facade of Novo Nordisk's office in Fremont, California
Manufacturing
Novo Continues Manufacturing Spending Spree With $400M Denmark Expansion, $200M Plant Purchase
December 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Sanofi's Distribution Center in Quebec, Canada
Radiopharmaceuticals
Sanofi Inks $326M Radiopharma Deal With Orano
October 17, 2024
 · 
2 min read
 · 
Tristan Manalac